Payload Information
General Information of This Payload
| Payload ID | PAY0WLXJM |
|||||
|---|---|---|---|---|---|---|
| Name | ZD06519 |
|||||
| Synonyms |
ZD06519
Click to Show/Hide
|
|||||
| Target | DNA topoisomerase 1 (TOP1) | |||||
| Structure |
|
|||||
| Formula | C25H24FN3O7 |
|||||
| Isosmiles | CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)cc1c2CNC(=O)OCCO |
|||||
| InChI |
InChI=1S/C25H24FN3O7/c1-3-25(34)17-7-20-21-15(10-29(20)22(31)16(17)11-36-23(25)32)14(9-27-24(33)35-5-4-30)13-6-12(2)18(26)8-19(13)28-21/h6-8,30,34H,3-5,9-11H2,1-2H3,(H,27,33)
|
|||||
| InChIKey |
SJLICXIYNPAXHJ-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
497.479 |
Polar area |
139.98 |
||
Complexity |
36 |
xlogp Value |
1.74562 |
|||
Heavy Count |
36 |
Rot Bonds |
5 |
|||
Hbond acc |
9 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
ZW191 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility: Locally advanced/unresectable or metastatic cancer (measurable per RECIST v1.1), ECOG 0-1, LVEF ≥50%, and adequate organ function. Exclusions: active malignancies requiring treatment, prior TOPO1i ADC therapy, uncontrolled organ dysfunction (renal/liver/pancreatic), or severe active infections (including SARS-CoV-2) needing systemic therapy.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06555744 | Phase Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary safety outcomes (Parts 1-2) include dose-limiting toxicities (DLTs) evaluated within 3 weeks, treatment-related adverse events (AEs), special interest AEs (AESIs), serious AEs (SAEs), and Grade 3+ lab abnormalities per CTCAE v5.0. Key efficacy measures (Part 2) focus on confirmed objective response rate (ORR) by RECIST v1.1 (CR/PR).
|
||||
| Other Endpoint |
Secondary endpoints (Parts 1-2) assess clinical benefit rate (CR/PR/non-CR non-PD/SD lasting ≥180 days), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and best overall response (BOR). Pharmacokinetics (serum concentrations & ADA development) will be monitored throughout the study.
|
||||